Skye Bioscience, Inc.
SKYE
$1.11
-$0.10-8.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.25M | 11.43M | 11.85M | 11.49M | 11.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Operating Expenses | 53.93M | 45.64M | 35.80M | 30.19M | 23.61M |
| Operating Income | -53.93M | -45.64M | -35.80M | -30.19M | -23.61M |
| Income Before Tax | -51.22M | -42.37M | -32.64M | -26.56M | -21.23M |
| Income Tax Expenses | 5.40K | 5.40K | 10.10K | 10.10K | 10.10K |
| Earnings from Continuing Operations | -51.23 | -42.37 | -32.65 | -26.57 | -21.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.23M | -42.37M | -32.65M | -26.57M | -21.24M |
| EBIT | -53.93M | -45.64M | -35.80M | -30.19M | -23.61M |
| EBITDA | -53.22M | -45.03M | -35.35M | -29.89M | -23.46M |
| EPS Basic | -1.29 | -1.07 | -0.83 | -0.73 | -0.84 |
| Normalized Basic EPS | -0.81 | -0.67 | -0.52 | -0.48 | -0.56 |
| EPS Diluted | -1.29 | -1.07 | -0.83 | -0.73 | -0.84 |
| Normalized Diluted EPS | -0.81 | -0.67 | -0.52 | -0.48 | -0.56 |
| Average Basic Shares Outstanding | 158.95M | 158.10M | 157.11M | 145.46M | 117.89M |
| Average Diluted Shares Outstanding | 158.95M | 158.10M | 157.11M | 145.46M | 117.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |